UnitedHealth Shares Fall 5.3% After Berkshire Exit and CEO Trial Evidence
UnitedHealth shares slid as much as 5.3% after Berkshire Hathaway liquidated its entire 5.04 million‐share position rebuilt less than a year earlier. Prosecutors introduced evidence in Luigi Mangione’s trial for the fatal shooting of UnitedHealthcare CEO Brian Thompson, heightening concerns over executive succession.
1. Berkshire Hathaway Exits UnitedHealth Stake
Berkshire Hathaway fully liquidated its roughly 5.04 million-share position in UnitedHealth, a stake it had rebuilt in the second quarter of 2025. The announcement triggered a premarket decline of up to 5.3%, reflecting investor scrutiny over medical costs, reimbursement trends and margin pressures.
2. Evidence Presented in CEO’s Shooting Trial
Prosecutors introduced evidence in the trial of Luigi Mangione for the fatal shooting of UnitedHealthcare CEO Brian Thompson. The presentation of key materials and witness accounts has intensified uncertainty around leadership continuity and succession planning at the company.